Key Anti-Fibrosis Associated Long Noncoding RNAs Identified in Human Hepatic Stellate Cell via Transcriptome...

Area of Science:

• Molecular Biology
• Genomics
• Cell Biology

Background:

• Hepatic fibrosis, a precursor to cirrhosis, is driven by activated hepatic stellate cells (HSCs).
• Understanding the regulatory mechanisms in HSC activation is crucial for developing anti-fibrosis therapies.

Purpose of the Study:

• To investigate the differential expression of long noncoding RNAs (lncRNAs) in activated human HSCs (hHSCs) compared to quiescent cells.
• To identify specific lncRNAs and their associated pathways regulating hHSC activation.

Main Methods:

• RNA sequencing (RNA-seq) to profile lncRNA expression in hHSCs.
• Bioinformatics analysis including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.
• Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) for validation of differentially expressed lncRNAs and lncRNA-mRNA co-expression.

Main Results:

• Identified 34,146 differentially expressed (DE) lncRNAs between activated and quiescent hHSCs.
• Several DE lncRNAs were found to regulate hHSC activation via pathways including DNA bending/packaging, growth factor binding, and the Hippo signaling pathway.
• Three lncRNAs were significantly associated with key fibrotic factors: connective tissue growth factor (CTGF), fibroblast growth factor 2 (FGF2), and netrin-4 (NTN4).

Conclusions:

• This study provides the first comprehensive insight into lncRNA expression profiles in activated human HSCs.
• Several identified lncRNAs demonstrate potential as therapeutic targets for reversing liver fibrosis.
• The findings highlight the critical role of lncRNAs in HSC activation and liver fibrogenesis.